Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has approved Juvisync (sitagliptin and simvastatin) by Merck for treatment of type 2 diabetes and lowering cholesterol.
Subscribe to our email newsletter
Juvisync combines Januvia (sitagliptin), the glucose-lowering medication with the cholesterol-lowering medication Zocor (simvastatin).
According to the company, Juvisync is said to provide blood sugar-lowering benefits of a DPP-4 inhibitor and the cholesterol-lowering benefits of simvastatin, with a dose of single tablet in a day.
The approval by FDA is followed by clinical bioequivalence studies in healthy subjects who showed administration of Juvisync is equivalent to co-administration of corresponding doses of the two individual medications, sitagliptin and simvastatin, as separate tablets.